ENTRY       D11328                      Drug
NAME        Solriamfetol hydrochloride (USAN);
            Sunosi (TN)
PRODUCT     SUNOSI (Axsome Therapeutics)
            SUNOSI (Jazz Pharmaceuticals)
FORMULA     C10H14N2O2. HCl
EXACT_MASS  230.0822
MOL_WEIGHT  230.6913
CLASS       Neuropsychiatric agent
             DG03059  Noradrenalin and dopamine reuptake inhibitor (NDRI)
REMARK      ATC code: N06BA14
            Chemical structure group: DG02989
            Product (DG02989): D11328<US>
EFFICACY    Wake-promoting agent, Noradrenalin and dopamine reuptake inhibitor
  DISEASE   Narcolepsy [DS:H01293]
COMMENT     Wake-promoting agent for the treatment of excessive sleepiness associated with narcolepsy or obstructive sleep apnea
TARGET      SLC6A2 (NAT1) [HSA:6530] [KO:K05035]
            SLC6A3 (DAT1) [HSA:6531] [KO:K05036]
  PATHWAY   hsa04721(6530+6531)  Synaptic vesicle cycle
            hsa04728(6531)  Dopaminergic synapse
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             N NERVOUS SYSTEM
              N06 PSYCHOANALEPTICS
               N06B PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS
                N06BA Centrally acting sympathomimetics
                 N06BA14 Solriamfetol
                  D11328  Solriamfetol hydrochloride (USAN) &lt;US&gt;
            USP drug classification [BR:br08302]
             Sleep Disorder Agents
              Wakefulness Promoting Agents
               Solriamfetol
                D11328  Solriamfetol hydrochloride (USAN)
            Drug groups [BR:br08330]
             Neuropsychiatric agent
              DG03059  Noradrenalin and dopamine reuptake inhibitor (NDRI)
               DG02989  Sorliamfetol
                D11328  Solriamfetol hydrochloride
            Target-based classification of drugs [BR:br08310]
             Transporters
              Solute carrier family
               SLC6
                SLC6A2 (NAT1)
                 D11328  Solriamfetol hydrochloride (USAN) &lt;US&gt;
                SLC6A3 (DAT1)
                 D11328  Solriamfetol hydrochloride (USAN) &lt;US&gt;
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D11328
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D11328
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D11328
            Drug groups [BR:br08330]
             Neuropsychiatric agent
              DG03059  Noradrenalin and dopamine reuptake inhibitor (NDRI)
               DG02989  Sorliamfetol
DBLINKS     CAS: 178429-65-7
            PubChem: 384585306
ATOM        15
            1   C8x C    13.7981  -16.1795
            2   C8x C    13.7981  -17.5803
            3   C8x C    15.0589  -18.2807
            4   C8x C    16.2496  -17.5803
            5   C8y C    16.2496  -16.1795
            6   C8x C    15.0589  -15.4791
            7   C1b C    17.5103  -15.4791
            8   C1c C    18.7010  -16.1795
            9   C1b C    19.8917  -15.4791
            10  O7a O    21.0824  -16.1795
            11  C7a C    22.2731  -15.4791
            12  N1a N    23.4638  -16.1795
            13  O6a O    22.2731  -14.0783
            14  N1a N    18.7010  -17.5803
            15  X   Cl   26.6000  -18.2000
BOND        14
            1     1   2 2
            2     2   3 1
            3     3   4 2
            4     4   5 1
            5     5   6 2
            6     1   6 1
            7     5   7 1
            8     7   8 1
            9     8   9 1
            10    9  10 1
            11   10  11 1
            12   11  12 1
            13   11  13 2
            14    8  14 1 #Down
///
